Use of nucleolin as a biomarker for lymphangiogenesis in a cancer prognosis and therapy
US-10054590-B2 · Aug 21, 2018 · US
This page is not indexed by search engines while we improve data quality.
Protgen Ltd — Physics
Protgen Ltd holds 4 patents in Physics, with representative filings summarized below.
| Metric | Value |
|---|---|
| Company | Protgen Ltd |
| Technology | Physics |
| Patents in slice | 4 |
| Recent patents in slice | 0 |
| First year | 2015 |
| Last year | 2018 |
Representative patents
Notable publications linking Protgen Ltd to Physics.
Use of nucleolin as a biomarker for lymphangiogenesis in a cancer prognosis and therapy
US-10054590-B2 · Aug 21, 2018 · US
Use of nucleolin as a biomarker for lymphangiogenesis in a cancer prognosis and therapy
US-10054590-B2 · Aug 21, 2018 · US
Use of nucleolin as a biomarker for lymphangiogenesis in a cancer prognosis and therapy
US-10054590-B2 · Aug 21, 2018 · US
Use of nucleolin as a biomarker for lymphangiogenesis in a cancer prognosis and therapy
US-10054590-B2 · Aug 21, 2018 · US
Recent filings
Latest patents from Protgen Ltd in Physics.
Use of nucleolin as a biomarker for lymphangiogenesis in a cancer prognosis and therapy
US-10054590-B2 · Aug 21, 2018 · US
Use of nucleolin as a biomarker for lymphangiogenesis in a cancer prognosis and therapy
US-10054590-B2 · Aug 21, 2018 · US
Use of nucleolin as a biomarker for lymphangiogenesis in a cancer prognosis and therapy
US-10054590-B2 · Aug 21, 2018 · US
Use of nucleolin as a biomarker for lymphangiogenesis in a cancer prognosis and therapy
US-10054590-B2 · Aug 21, 2018 · US
Use of nucleolin as a biomarker for lymphangiogenesis in a cancer prognosis and therapy
US-10054590-B2 · Aug 21, 2018 · US
Related pages
Navigate to parent entity pages.